Recent studies on
radiofrequency catheter ablation (RFCA) in
atrial fibrillation show its
effectiveness in
heart failure (HF)
patients; hence,
tachycardia-induced
cardiomyopathy (T-
CMP) is gaining
attention.
Tachycardia-mediated
cardiomyopathy is a reversible left ventricular (LV) dysfunction, which can be induced by any
tachyarrhythmia. Early recognition of T-
CMP with appropriate
treatment of the
arrhythmia culprit
will lead to the recovery of LV function.
Patients with
tachycardia and
LV dysfunction should be suspected of having T-
CMP, with or without established
etiology of HF, because T-
CMP may present by itself or contribute as a co-existent component.
Therapeutic options include rate control,
anti-arrhythmic drugs, or
catheter ablation. Unlike in
animal models, clinical data on
human T-
CMP is limited. Hence,
future research should be more focused on
tachyarrhythmia-induced
cardiomyopathy as its burden is increasing.